Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 2, pp. 244-256
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 7, 2018
- Revision received October 2, 2018
- Accepted December 3, 2018
- Published first January 18, 2019.
Article Versions
- Previous version (January 18, 2019 - 08:07).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Benjamin Murter1,
- Xiaoyu Pan1,
- Eran Ophir2,
- Zoya Alteber2,
- Meir Azulay2,
- Rupashree Sen1,
- Ofer Levy2,
- Liat Dassa2,
- Ilan Vaknin2,
- Tal Fridman-Kfir2,
- Ran Salomon2,
- Achinoam Ravet2,
- Ada Tam1,
- Doron Levin2,
- Yakir Vaknin2,
- Evgeny Tatirovsky2,
- Arthur Machlenkin2,
- Drew Pardoll1, and
- Sudipto Ganguly1,*
- 1Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland.
- 2Compugen Ltd, Holon, Israel.
- ↵*Corresponding Author:
Sudipto Ganguly, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB-1 Room 441, Baltimore, MD 21287. Phone: 410-614-2948; E-mail: sgangul8{at}jhmi.edu
B. Murter and X. Pan contributed equally to this article.
February 2019
Volume 7, Issue 2
Volume 7, Issue 2
Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
Jump to section
Advertisement